Identificación y tratamiento de los pacientes con miocardiopatía hipertrófica y riesgo de muerte súbita

McKenna, William J.; Iglesias, Lorenzo Monserrat

doi:10.1016/s0300-8932(00)75069-x

Cited by 23 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current guidelines state that the HCM diagnose must be considered in the presence of a maximum thickening of the ventricular wall of 15 mm or more, or of 13 to 14 mm in the presence of familar history of HCM (or compatible electrocardiogram), that is detected either by echocardiography or MRI. 3) 4) 12) 13) Paradoxically, in our study, the survival rate was worse for patients with apical HCM, followed by those with obstructive and nonobstructive septal asymmetric HCM and patients showing concentric HCM had the best survival rates. There is a significant difference in the survival rates which decline in 50% in a 20 month-period.…”

Section: Discussioncontrasting

confidence: 46%

Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World

Espínola‐Zavaleta

Vega

Basto

et al. 2015

J Cardiovasc Ultrasound

View full text Add to dashboard Cite

BackgroundHypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease with diverse phenotipyc, genetic expession and clinical presentations. The evolution of patients with HCM in Latin America has not been properly described being the frequency, the long-term prognosis as well as the predominant phenotypic expression still unknown. The aim of this study was to determine the survival rate of HCM patients having different phenotypes in a Mexican cohort of patients.MethodsClinical and echocardiographic data obtained from 77 Mexican patients with recently diagnosed HCM were analyzed. The follow-up was of 12.5 years.Results96.1% of patients were in functional class I/II according to the New York Heart Association, 2.6% in class III and 1.3% in class IV. Only 3.9% of them went to surgery for myectomy. During the follow-up, 17 patients (22%) died: 4/9 (44%) had apical HCM, 5/20 (25%) had obstructive septal asymmetric HCM, 6/35 (17%) had nonobstructive septal asymmetric HCM and 2/3 (15%) had concentric HCM. The survival rate was worse for patients with apical HCM, followed by those with obstructive and nonobstructive septal asymmetric HCM and patients showing concentric HCM had the best survival rates. There is significant difference in survival rates which declined in 65% in a 9 years-period. Log rank test showed significant differences (p < 0.002).ConclusionThe survival rate of patients with HCM was worse in those with apical variety. The majority of patients received medical treatment. The indication for myectomy was below that observed in other international centers.

show abstract

Section: Discussioncontrasting

confidence: 46%

Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World

Espínola‐Zavaleta

Vega

Basto

et al. 2015

J Cardiovasc Ultrasound

View full text Add to dashboard Cite

show abstract

“…EPS in the HCM risk stratification is controversial in the literature 28,29 , and the findings in our study were also inconclusive. Two patients with induced SVT did not present clinical arrhythmia in 2 years of follow-up, and in one patient with SVT reverted by ICD shock therapy no arrhythmia was induced in the EPS.…”

Section: Original Articlecontrasting

confidence: 82%

Cardiomiopatia hipertrófica: importância dos eventos arrítmicos em pacientes com risco de morte súbita

Medeiros¹,

Filho²,

Arteaga³

et al. 2006

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

1- occurrence of arrhythmic events in 50% of the patients; most of them (62%) were ventricular tachycardia, whether sustained (31%) or nonsustained (31%); in the remaining patients paroxysmal supraventricular tachycardia was observed. 2- recurrent syncope in the minority of the patients (16%), however not associated with the presence of arrhythmic events. 3- the presence of an interventricular septal thickness greater than 30 mm in the echocardiogram was associated with early shock therapy (p = 0.003). 4- absence of clinical or functional predictors.

show abstract

“…It is associated with a higher incidence of ventricular arrhythmias, atrial fibrillation, symptomatic heart failure and sudden death, and requires therapeutic adjustments. 1,7,27 It would be interesting to evaluate in prospective studies whether CT-1 levels could be early predictors of this evolution.…”

Section: Discussionmentioning

confidence: 99%

Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy

Monserrat

López

González

et al. 2010

European Heart Journal

View full text Add to dashboard Cite

AimsCardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM).Methods and resultsThe study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocardiogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the Spirito's LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls, patients with HCM exhibited higher (P < 0.001) plasma CT-1 levels. Significant correlations were found between CT-1 and maximal LV wall thickness (r = 0.284, P = 0.001) and the Spirito's LVH score (r = 0.287, P = 0.006) in HCM patients. In addition, the levels of CT-1 were higher (P = 0.02) in patients with severe LVH (maximal LV wall thickness ≥30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness <30 mm).ConclusionsThese findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy.

show abstract

Identificación y tratamiento de los pacientes con miocardiopatía hipertrófica y riesgo de muerte súbita

Cited by 23 publications

References 56 publications

Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World

Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World

Cardiomiopatia hipertrófica: importância dos eventos arrítmicos em pacientes com risco de morte súbita

Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy

Contact Info

Product

Resources

About